# Novelix Pharma (NSE: NOVELIX) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NOVELIX · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹181 Cr, it ranks 2337th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.

Its return on equity was −24.3% in FY22. In Q2 FY23, the quarter ended 30 Sep 2022, revenue was ₹1 Cr (−49.6% year on year) and net profit −₹0 Cr (−140.0%), on a consolidated basis. Promoters held 54.29% of the company as of 17 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹181 Cr |
| ROE | −24.3% (FY22) |
| ROCE | −27.2% (FY22) |
| Debt to equity | 0.02 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q2 FY23 | ₹1 Cr | −49.6% | −₹0 Cr | −140.0% | −₹0.19 |
| Q1 FY23 | ₹1 Cr | −68.7% | −₹0 Cr | — | −₹0.11 |
| Q4 FY22 | ₹1 Cr | −72.5% | −₹2 Cr | — | −₹1.67 |
| Q3 FY22 | ₹1 Cr | −49.3% | −₹1 Cr | — | −₹0.77 |
| Q2 FY22 | ₹2 Cr | −0.8% | ₹0 Cr | — | ₹0.39 |
| Q1 FY22 | ₹4 Cr | +112.2% | −₹0 Cr | — | −₹0.18 |
| Q4 FY21 | ₹3 Cr | −5.6% | −₹3 Cr | −11,000.0% | −₹4.05 |
| Q3 FY21 | ₹2 Cr | −13.1% | −₹0 Cr | — | −₹0.26 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY22 | ₹9 Cr | −₹2 Cr |
| FY21 | ₹9 Cr | −₹4 Cr |
| FY20 | ₹10 Cr | −₹0 Cr |
| FY19 | ₹10 Cr | −₹0 Cr |
| FY18 | ₹11 Cr | −₹0 Cr |
| FY17 | ₹9 Cr | ₹0 Cr |

## Shareholding (17 Jul 2026)

- Promoters: 54.29%
- Non-institutions: 45.71%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [OXYGENTA PHARMA](https://app.pivotnow.in/stock/OXYGENTAPH) | — | ₹185 Cr | — | — |
| [Accretion Nutra](https://app.pivotnow.in/stock/ANL) | — | ₹184 Cr | — | — |
| [Earkart](https://app.pivotnow.in/stock/EARKART) | — | ₹182 Cr | — | — |
| [Medico Remedies](https://app.pivotnow.in/stock/MEDICO) | ₹21.68 | ₹180 Cr | 13.7 | — |
| [Take Solutions](https://app.pivotnow.in/stock/TAKE) | ₹11.96 | ₹177 Cr | 41.2 | — |
| [Bal Pharma](https://app.pivotnow.in/stock/BALPHARMA) | ₹109.58 | ₹174 Cr | 27.7 | — |

## Questions and answers

### What is the market cap of Novelix Pharma?

Novelix Pharma's market capitalisation is ₹181 Cr (₹181 Cr) at the 19 Oct 2026 close, ranking 2337th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Novelix Pharma?

Return on equity was −24.3% in FY22 and return on capital employed was −27.2% in FY22 (consolidated figures).

### Is Novelix Pharma a debt-free company?

Novelix Pharma is close to debt-free: its debt-to-equity ratio was 0.02 in FY22.

### What were Novelix Pharma's latest quarterly results?

For Q2 FY23 (quarter ended 30 Sep 2022), Novelix Pharma reported revenue of ₹1 Cr, −49.6% year on year, and net profit of −₹0 Cr, −140.0% year on year.

### What is the shareholding pattern of Novelix Pharma?

As of 17 Jul 2026: promoters 54.29%, non-institutions 45.71%.

### Who are Novelix Pharma's competitors?

The listed Pharma & Healthcare companies closest to Novelix Pharma by market cap are OXYGENTA PHARMA, Accretion Nutra, Earkart, Medico Remedies, Take Solutions and Bal Pharma.

### Is Novelix Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Novelix Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NOVELIX against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.